[A case report of advanced breast cancer effectively treated with etoposide, adriamycin and cis-platinum combination therapy]. 1988

T Kurihara, and O Teshigawara, and S Owada, and T Fujii
Department of Surgery, Numata National Hospital.

A 61-year-old woman with left advanced breast cancer (T3a, N2, M0, Stage IIIa) underwent preoperative chemotherapy. The regimen consisted of etoposide 70 mg/m2 (day 4, 5, 6 i.v.), adriamycin 20 mg/m2 (day 1, 7 i.v.) and cis-platinum 40 mg/m2 (day 2, 8 i.v.). By the third week of administration, the size of the breast tumor reduced markedly, with the rate of 97%, resulting in partial response. Following preoperative combination-chemotherapy, a left extended radical mastectomy was performed. Histological findings of the resected specimen showed sufficient effects of chemotherapy; degeneration of tumor cells, infiltration of histiocytes and fibrosis of stroma. After operation, chemotherapy with the same dosage and sequential irradiation were undergone. As the side effect of this chemotherapy, slight nausea, vomiting and leucocytopenia were observed. The result of this case suggested that combination-chemotherapy with etoposide, adriamycin and cisplatinum was an effective chemotherapy for advanced breast cancer.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Kurihara, and O Teshigawara, and S Owada, and T Fujii
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
December 2023, Gan to kagaku ryoho. Cancer & chemotherapy,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
February 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
September 1984, British journal of obstetrics and gynaecology,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
August 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
June 1985, European journal of cancer & clinical oncology,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
December 1990, Journal of chemotherapy (Florence, Italy),
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
August 1988, American journal of clinical oncology,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
T Kurihara, and O Teshigawara, and S Owada, and T Fujii
December 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!